Выживаемость лабораторных животных с перевиваемой асцитной гепатомой Зайдела при измененном тиреоидном статусе: ПАТОФИЗИОЛОГИЯ — МЕДИЦИНЕ

Альбина Александровна  Кондратенко; Наталья Дмитриевна  Прохорова; Станислав Юрьевич  Пудов; Павел Алексеевич  Слижов; Владимир Михайлович  Рябов; Ирина Владимировна  Гужова; Борис Александрович  Маргулис; Руслан Иванович  Глушаков

doi:10.56871/RBR.2026.71.27.001

Survival rate of hyperthyroid and hypothyroid rats with transplantable ascitic Zajdela’s hepatoma

PATHOPHYSIOLOGY — MEDICINE

Albina A. Kondratenko Saint Petersburg State Pediatric Medical University; Kirov Military Medical Academy https://orcid.org/0000-0002-8511-5864
Natalia D. Prohorova Kirov Military Medical Academy https://orcid.org/0000-0001-6485-1056
Stanislav Yu. Pudov Kirov Military Medical Academy https://orcid.org/0009-0004-5536-5549
Pavel A. Slizhov Kirov Military Medical Academy https://orcid.org/0000-0001-6885-5273
Vladimir M. Ryabov Institute of Cytology of the Russian Academy of Sciences https://orcid.org/0000-0001-5908-0584
Irina V. Guzhova Institute of Cytology of the Russian Academy of Sciences https://orcid.org/0000-0002-8775-7713
Boris A. Margulis Institute of Cytology of the Russian Academy of Sciences https://orcid.org/0000-0002-2608-0147
Ruslan I. Glushakov Saint Petersburg State Pediatric Medical University; Kirov Military Medical Academy; Institute of Experimental Medicine https://orcid.org/0000-0002-0161-5977

Keywords:

Zajdela’s (Seidel’s) hepatoma thyroid hormones hyperthyroidism hypothyroidism cisplatin гепатома Зайделя гормоны щитовидной железы гипертиреоз гипотиреоз цисплатин

Abstract

Introduction.The nongenomic actions of thyroid hormone begin at receptors in the plasma membrane, mitochondria or cytoplasm. Nongenomic actions initiated at the plasma membrane by thyroid hormone via integrinαvβ3can induce gene expression that affects angiogenesis and cell proliferation, therefore, both nongenomic and genomic effects can overlap in the nucleus. Scientific data demonstrate that excess concentrations of thyroid hormone are factors accelerating the natural history of cancer development. On the contrary, hypothyroidism for lymphoproliferative diseases and hepatocellular cancer is a risk factor for cancer progression.Aim.In the present study, the effect of drug-induced hypo- and hyperthyroidism was evaluated on the survival rate of rats with transplantable Seidel’s ascites hepatoma.Materials and methods.This study examined the effect of hyper- and hypothyroidism on the survival of Seidel’s ascites hepatoma bearing rats. Hepatoma cells were implanted intraperitoneally in male rats (n=48). Hypo- and hyperthyroidism was induced by oral administration of propylthiouracil (PTU) and L-thyroxine (Т4) 1.0 and 5.0 mg/kg body weight daily, respectively. Comparison group (n=12) were treated with cisplatin intraperitoneally one-time of 20,0 mg/kg body weight.Results.Survival analysis showed that cisplatin administration increased the life expectancy of laboratory animals by 32.1%, while hypo- and hyperthyroidism decreased the life expectancy by 4.8 and 10.7%, respectively. The median survival time of the euthyroid group was 8.0 (7.41–8.59) days, median survival time of the comparison group was 9.0 (8.78–10.2) days. Median survival time of the hypo- and hyperthyroid groups were 6.0 (5.75–6.92) and 6.0 (5.33–6.67) days, respectively (p=0.304).Conclusions.PTU-induced hypothyroidism and T4-induced hyperthyroidism leads to a decrease in the survival rate of laboratory animals with transplantable Seidel’s ascites hepatoma compared to the euthyroid group.

Author Biographies

Albina A. Kondratenko, Saint Petersburg State Pediatric Medical University; Kirov Military Medical Academy

Cand. Sci. (Biol.), Assistant Professor, Department of Histology and Embryology named after Professor A.G. Knorre, Saint Petersburg State Pediatric Medical University; Research of the Department (medical and biological research) of the Research Center of Kirov Military Medical Academy

Natalia D. Prohorova, Kirov Military Medical Academy

Postgraduate Student of the Department (medical and biological research) of the Research Center

Stanislav Yu. Pudov, Kirov Military Medical Academy

Postgraduate Student of the Department (medical and biological research) of the Research Center

Pavel A. Slizhov, Kirov Military Medical Academy

Junior Researcher of the Research Laboratory (Artificial Organs) of the Research Department (Medical and Biological Research) of the Research Center

Vladimir M. Ryabov, Institute of Cytology of the Russian Academy of Sciences

Junior Researcher

Irina V. Guzhova, Institute of Cytology of the Russian Academy of Sciences

Dr. Sci. (Biol.), Project Leader

Boris A. Margulis, Institute of Cytology of the Russian Academy of Sciences

Dr. Sci. (Biol.), Project Leader

Ruslan I. Glushakov, Saint Petersburg State Pediatric Medical University; Kirov Military Medical Academy; Institute of Experimental Medicine

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics, Saint Petersburg State Pediatric Medical University Ministry; Head of the Department (Medical and Biological Research) of the Research Center, Kirov Military Medical Academy; Head of the Physiological Department named after Academician I.P. Pavlov, Institute of Experimental Medicine

References

1. Глушаков Р.И., Прошин С.Н., Тапильская Н.И. Частота возникновения опухоли молочной железы при индуцированном гипертиреозе в эксперименте. Бюллетень экспериментальной биологии и медицины. 2013;156(8):212–214. EDN: QNLGNF.

2. Aranda A. Thyroid hormone action by genomic and nongenomic molecular mechanisms. Thyroid Hormones: Methods and Protocols. New York: Springer US; 2024. P. 17–34.

3. Nekrasov M.S., Paremskiy E.V., Tapilskaya N.I. et al. The prevalence of malignant tumours among women with a history of hyperthyroidism: St. Petersburg case-control study. Ann Rom Soc Cell Biol. 2021;25(4):9070–9079.

4. Frau C., Loi R., Petrelli A. et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology. 2015;61(1):249–259. https://doi.org/10.1002/hep.27399.

5. Hassan M., Kaseb M., Li D. et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009;49(5):1563–1570. https://doi.org/10.1002/hep.22793.

6. Zajdela F. Experimental hepatomas; some cytological aspects. Arch Mal Appar Dig Mal Nutr. 1963;52:1213-1217.

7. Hercbergs A.H., Ashur-Fabian O., Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):432–436. https://doi.org/10.1097/MED.0b013e32833d9710.

8. Mishkin S.Y. Pollack R., Yalovsky M.A. et al. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res. 1981;41(5):3040–3045.

9. Marino L., Kim A., Ni B., Celi F.S. Thyroid hormone action and liver disease, a complex interplay. Hepatology. 2025;81(2):651–669. https://doi.org/10.1097/HEP.0000000000000551.

10. Reddy A., Dash C., Leerapun A. et al. Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol. 2007;5(1):118–123.

11. Кондратенко А.А., Прохорова Н.Д., Минченко А.А. и др. Морфофункциональное состояние печени крыс при моделировании жирового гепатоза и измененном тиреоидном статусе. Российские биомедицинские исследования. 2024;9(3):5–14. https://doi.org/10.56871/RBR.2024.58.48.001.

12. Chung I.H., Chen C.Y., Lin Y.H. et al. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget. 2015;6(17):15050–15064. https://doi.org/10.18632/oncotarget.3670.

Survival rate of hyperthyroid and hypothyroid rats with transplantable ascitic Zajdela’s hepatoma: PATHOPHYSIOLOGY — MEDICINE. (2026). Russian Biomedical Research, 11(2), 7-15. https://doi.org/10.56871/RBR.2026.71.27.001

Download Citation

How to Cite